SiyangLengMD

Oncology • New York, NY

Hematologic Oncology

Physician

Join to view full profile

Dr. Leng is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Leng's full profile

Already have an account?

Office
161 Fort Washington Avenue
0
New York, NY 10032

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2013 - 2016
UPMC Medical EducationResidency, Internal Medicine, 2009 - 2012
State University of New York Downstate Medical Center College of MedicineClass of 2009

Certifications & Licensure

NY State Medical License 2013 - 2026
PA State Medical License 2012 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study.
Scott F Huntington, Wendy Y Cheng, Eric M Sarpong, Siyang Leng, Mohammed Z H Farooqui
Leukemia & Lymphoma. 2024-07-01
3 citations
Real-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia.
Scott F Huntington, Enrico de Nigris, Justin T Puckett, Sachin Kamal-Bahl, Mohammed Farooqui
Cancer Medicine. 2024-01-01
1 citations
Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia.
Scott F Huntington, Enrico de Nigris, Justin Puckett, Sachin Kamal-Bahl, Mohammed Farooqui
Leukemia & Lymphoma. 2023-12-01

Abstracts/Posters

Combination Chemotherapy with Carfilzomib, Bendamustine and Dexamethasone Is Highly Active for Therapy of Newly Diagnosed Multiple Myeloma-Results of Single Center Pha...
Siyang Leng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Factors associated with over and underuse of response evaluation in elderly myeloma patients.
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
A phase 1/2 study of carfilzomib, bendamustine, and dexamethasone (CBD) in newly diagnosed multiple myeloma patients.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018